Cost Evaluation of Inhaler Therapies Used in Respiratory Diseases : 1998--2015 Period in Turkey
Copyright © 2017. Published by Elsevier Inc..
BACKGROUND: With the rise in life expectancy, the burden of chronic diseases, including obstructive pulmonary diseases, has increased throughout the world.
OBJECTIVES: To evaluate the sales trends of inhaler pharmaceuticals.
METHODS: The changes in box sales and sales amounts (in Turkish lira) of inhaler pharmaceuticals during the period 1998 to 2015 were examined and sales were projected for the next 3 years. Pharmaceuticals were classified according to form and pharmacological groups.
RESULTS: The sales of inhaler pharmaceuticals have increased rapidly since 2008. The fastest increase in consumption has occurred in short-acting β2 agonist preparations and nebulizer pharmaceuticals. Inhaled corticosteroid and long-acting β2 agonist combination sales have been the highest since 2002, when these products entered the Turkish market.
CONCLUSIONS: The inhaler pharmaceutical market has grown over the years, and this growth will continue in the future. The increased use of short-acting preparations, which should be used as symptom relievers, indicates that treatment management continues to be inadequate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Value in health regional issues - 13(2017) vom: 31. Sept., Seite 31-38 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bayar, Banu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 29.10.2018 Date Revised 29.10.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vhri.2017.07.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM277418712 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM277418712 | ||
| 003 | DE-627 | ||
| 005 | 20231225014150.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vhri.2017.07.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0924.xml |
| 035 | |a (DE-627)NLM277418712 | ||
| 035 | |a (NLM)29073985 | ||
| 035 | |a (PII)S2212-1099(17)30050-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bayar, Banu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost Evaluation of Inhaler Therapies Used in Respiratory Diseases |b 1998--2015 Period in Turkey |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.10.2018 | ||
| 500 | |a Date Revised 29.10.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: With the rise in life expectancy, the burden of chronic diseases, including obstructive pulmonary diseases, has increased throughout the world | ||
| 520 | |a OBJECTIVES: To evaluate the sales trends of inhaler pharmaceuticals | ||
| 520 | |a METHODS: The changes in box sales and sales amounts (in Turkish lira) of inhaler pharmaceuticals during the period 1998 to 2015 were examined and sales were projected for the next 3 years. Pharmaceuticals were classified according to form and pharmacological groups | ||
| 520 | |a RESULTS: The sales of inhaler pharmaceuticals have increased rapidly since 2008. The fastest increase in consumption has occurred in short-acting β2 agonist preparations and nebulizer pharmaceuticals. Inhaled corticosteroid and long-acting β2 agonist combination sales have been the highest since 2002, when these products entered the Turkish market | ||
| 520 | |a CONCLUSIONS: The inhaler pharmaceutical market has grown over the years, and this growth will continue in the future. The increased use of short-acting preparations, which should be used as symptom relievers, indicates that treatment management continues to be inadequate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a inhaler pharmaceuticals | |
| 650 | 4 | |a obstructive pulmonary diseases | |
| 650 | 4 | |a pharmaceutical economics | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 700 | 1 | |a Kutkan, Nurcan Uman |e verfasserin |4 aut | |
| 700 | 1 | |a Şafak Yılmaz, Esra |e verfasserin |4 aut | |
| 700 | 1 | |a Tolun, Çiğdem |e verfasserin |4 aut | |
| 700 | 1 | |a Doğan, Engin |e verfasserin |4 aut | |
| 700 | 1 | |a Atikeler, Enver Kağan |e verfasserin |4 aut | |
| 700 | 1 | |a Vural, Elif Hilal |e verfasserin |4 aut | |
| 700 | 1 | |a Babacan, Salih |e verfasserin |4 aut | |
| 700 | 1 | |a Karabekmez, Nurgül |e verfasserin |4 aut | |
| 700 | 1 | |a Beyan, Aslıhan |e verfasserin |4 aut | |
| 700 | 1 | |a Vural, İsmail Mert |e verfasserin |4 aut | |
| 700 | 1 | |a Oğuzülgen, İpek Kıvılcım |e verfasserin |4 aut | |
| 700 | 1 | |a Bektemür, Güven |e verfasserin |4 aut | |
| 700 | 1 | |a Malhan, Simten |e verfasserin |4 aut | |
| 700 | 1 | |a Kahveci, Rabia |e verfasserin |4 aut | |
| 700 | 1 | |a Altın, Sedat |e verfasserin |4 aut | |
| 700 | 1 | |a Alkan, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Eroğlu, Hakan |e verfasserin |4 aut | |
| 700 | 1 | |a Gürsöz, Hakkı |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Value in health regional issues |d 2012 |g 13(2017) vom: 31. Sept., Seite 31-38 |w (DE-627)NLM25439745X |x 2212-1102 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2017 |g day:31 |g month:09 |g pages:31-38 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vhri.2017.07.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2017 |b 31 |c 09 |h 31-38 | ||